These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 476702)

  • 1. Effect of splenectomy on the immune response of BALB/c mice bearing an immunoglobulin M plasmacytoma (TEPC-183).
    Havas HF; Berney S; Goodis A; Schiffman G
    Cancer Res; 1979 Sep; 39(9):3783-7. PubMed ID: 476702
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunosupression of the primary and secondary immune response by an IgM plasmacytoma (TEPC-183).
    Havas HF; Schiffman GD; Fenton M; Goodis A; Braverman S
    Immunology; 1979 Feb; 36(2):191-7. PubMed ID: 35463
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of cyclophosphamide on the immune response of BALB/c mice bearing an immunoglobulin M plasmacytoma (TEPC-183).
    Havas HF; Schiffman G
    Cancer Res; 1981 Mar; 41(3):801-7. PubMed ID: 7459867
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunosuppression in BALB/c mice bearing the plasmacytoma TEPC-183: massive increase in red pulp macrophages induced by the tumour.
    Joshua DE; Humphrey JH; Grennan D; Brown G
    Immunology; 1980 Jun; 40(2):223-8. PubMed ID: 7409859
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of TEPC-183 plasmacytoma on resistance of passively or actively immunized BALB/c mice to infection with Streptococcus pneumoniae.
    Havas HF; Schiffman G; Schmitz J
    Cancer Res; 1984 Aug; 44(8):3299-302. PubMed ID: 6744264
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of an IgM plasmacytoma (TEPC-183) on the primary immune response of BALB/c mice.
    Havas HF; Schiffman G
    Immunology; 1978 Jan; 34(1):1-8. PubMed ID: 23993
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of plasmacytomas on serum immunoglobulin levels of BALB/c mice.
    Fenton MR; Havas HF
    J Immunol; 1975 Feb; 114(2 pt 2):793-801. PubMed ID: 1089719
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of T, B and adherent cells in the in vitro immune response of TEPC-183-bearing mice.
    Patel M; Havas HF
    Immunology; 1982 May; 46(1):97-105. PubMed ID: 6978846
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cellular changes and antitumor responses in the plasmacytoma-bearing mouse following cyclophosphamide treatment.
    Shanahan TC; Ceglowski WS; Havas HF
    Cancer Res; 1985 Dec; 45(12 Pt 1):6463-70. PubMed ID: 2866030
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulation of immune responses against the syngeneic ADJ-PC-5 plasmacytoma in BALB/c mice. I. Analysis of immune parameters involved.
    Cihak J; Ziegler HW; Kölsch E
    Immunology; 1981 May; 43(1):133-43. PubMed ID: 6265346
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Melphalan-induced enhancement of antitumor immune reactivity in thymocytes of adult BALB/c mice bearing a large MOPC-315 tumor.
    Bartik MM; Takesue BY; Mokyr MB
    Cancer Res; 1987 Sep; 47(18):4848-55. PubMed ID: 3497711
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypogammaglobulinemia in experimental myeloma: the role of suppressor factors from mononuclear phagocytes.
    Krakauer RS; Strober W; Waldmann TA
    J Immunol; 1977 Apr; 118(4):1385-90. PubMed ID: 850068
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of B-lymphocyte clonal proliferation by spleen cells from plasmacytoma-bearing mice.
    Hamburger AW
    J Natl Cancer Inst; 1980 Dec; 65(6):1337-43. PubMed ID: 6968847
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The mode of action of splenic suppressor cells in murine plasmacytoma.
    Chen Y; Heller P
    Clin Exp Immunol; 1981 Sep; 45(3):514-22. PubMed ID: 6461449
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regulation of immune responses aginst the syngeneic ADJ-PC-5 plasmacytoma in BALB-c mice. III. Induction of specific T suppressor cells to the BALB/c plasmacytoma ADJ-PC-5 during early stages of tumorigenesis.
    Haubeck HD; Kölsch E
    Immunology; 1982 Nov; 47(3):503-10. PubMed ID: 6215340
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunosuppression in plasmacytoma: induction of suppressor cells.
    Chen Y; Hwang LT; Heller P
    Clin Exp Immunol; 1982 Jan; 47(1):191-6. PubMed ID: 6212173
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Some characteristics of the cyclophosphamide-induced immunopotentiating cells in the spleen of mice bearing a large MOPC-315 tumor.
    Mokyr MB; Ye QW
    Cancer Res; 1985 Oct; 45(10):4932-9. PubMed ID: 4027979
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cellular specificity of plasmacytoma-induced immunosuppression.
    Zolla-Pazner S; Sullivan B; Richardson D
    J Immunol; 1976 Aug; 117(2):563-8. PubMed ID: 1084903
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Generation of anti-MOPC-315 cytotoxicity in uneducated or in vitro educated spleen cells from normal or MOPC-315 tumor-bearing mice pretreated in vivo with Bacillus Calmette-Guérin.
    Braun DP; Mokyr MB; Dray S
    Cancer Res; 1978 Jun; 38(6):1626-32. PubMed ID: 647676
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Myeloma-induced immunosuppression: a multistep mechanism.
    Katzmann JA
    J Immunol; 1978 Oct; 121(4):1405-9. PubMed ID: 701801
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.